The Company is headquartered in New York, NY. As of August 2009, NexGenix has 7 employees and supports a number of FTEs at multiple CROs. To date, the Company has raised approximately $14 M from angel investors. In addition, the Company has received non-dilutive grant funding of approximately $1.1 million from the U.S. Department of Defense, and seed funds from the Childrens Tumor Foundation
NexGenix believes that its novel series of Hsp90 inhibitor compounds and discovery partnership with ULP establish the Company as one of the leaders in the field of Hsp90 inhibitor research and development. The Company's objective is to leverage its expertise in Hsp90 inhibition to develop targeted treatments for diseases of in areas of significant unmet medical need such as glioblastoma and other cancers, neurodegenerative diseases, and NF. Our strategy for accomplishing this objective includes:
- Selecting a lead Hsp90 compound for further investigation in a clinical setting.
- Completing IND-enabling preclinical work for our lead series of Hsp90 compounds for clinical evaluation in glioblastoma patients.
- Operating our business optimally through outsourcing arrangements where we utilize R&D expertise in a cost-effective manner.